Literature DB >> 21131142

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.

Matthew W Johnson1, Katherine A MacLean, Chad J Reissig, Thomas E Prisinzano, Roland R Griffiths.   

Abstract

Salvinorin A is a potent, selective nonnitrogenous kappa opioid agonist and the known psychoactive constituent of Salvia divinorum, a member of the mint family that has been used for centuries by Mazatec shamans of Mexico for divination and spiritual healing. S. divinorum has over the last several years gained increased popularity as a recreational drug. This is a double-blind, placebo controlled study of salvinorin A in 4 psychologically and physically healthy hallucinogen-using adults. Across sessions, participants inhaled 16 ascending doses of salvinorin A and 4 intermixed placebo doses under comfortable and supportive conditions. Doses ranged from 0.375 μg/kg to 21 μg/kg. Subject-rated drug strength was assessed every 2 min for 60 min after inhalation. Orderly time- and dose-related effects were observed. Drug strength ratings peaked at 2 min (first time point) and definite subjective effects were no longer present at approximately 20 min after inhalation. Dose-related increases were observed on questionnaire measures of mystical-type experience (Mysticism Scale) and subjective effects associated with classic serotonergic (5-HT2(A)) hallucinogens (Hallucinogen Rating Scale). Salvinorin A did not significantly increase heart rate or blood pressure. Participant narratives indicated intense experiences characterized by disruptions in vestibular and interoceptive signals (e.g., change in spatial orientation, pressure on the body) and unusual and sometimes recurring themes across sessions such as revisiting childhood memories, cartoon-like imagery, and contact with entities. Under these prepared and supportive conditions, salvinorin A occasioned a unique profile of subjective effects having similarities to classic hallucinogens, including mystical-type effects.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21131142      PMCID: PMC3089685          DOI: 10.1016/j.drugalcdep.2010.11.005

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  27 in total

Review 1.  Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.

Authors:  Douglas J Sheffler; Bryan L Roth
Journal:  Trends Pharmacol Sci       Date:  2003-03       Impact factor: 14.819

Review 2.  Interactions between kappa opioid agonists and cocaine. Preclinical studies.

Authors:  N K Mello; S S Negus
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

3.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

4.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

5.  Salvia divinorum: exposures reported to a statewide poison control system over 10 years.

Authors:  Rais Vohra; Andrew Seefeld; F Lee Cantrell; Richard F Clark
Journal:  J Emerg Med       Date:  2009-09-17       Impact factor: 1.484

Review 6.  Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A.

Authors:  L J Valdés
Journal:  J Psychoactive Drugs       Date:  1994 Jul-Sep

7.  Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A.

Authors:  Mark Mowry; Michael Mosher; Wayne Briner
Journal:  J Psychoactive Drugs       Date:  2003 Jul-Sep

8.  The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.

Authors:  Eduardo R Butelman; Todd J Harris; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2003-10-30       Impact factor: 4.530

9.  Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Authors:  Bryan L Roth; Karen Baner; Richard Westkaemper; Daniel Siebert; Kenner C Rice; SeAnna Steinberg; Paul Ernsberger; Richard B Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

10.  Salvia divinorum and salvinorin A: new pharmacologic findings.

Authors:  D J Siebert
Journal:  J Ethnopharmacol       Date:  1994-06       Impact factor: 4.360

View more
  47 in total

1.  Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

Authors:  Eduardo R Butelman; Michael Caspers; Kimberly M Lovell; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  J Pharmacol Exp Ther       Date:  2012-03-20       Impact factor: 4.030

2.  Use of Salvia divinorum in a nationally representative sample.

Authors:  Brian E Perron; Brian K Ahmedani; Michael G Vaughn; Joseph E Glass; Arnelyn Abdon; Li-Tzy Wu
Journal:  Am J Drug Alcohol Abuse       Date:  2011-08-11       Impact factor: 3.829

Review 3.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

4.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

5.  Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A.

Authors:  Katherine M Prevatt-Smith; Kimberly M Lovell; Denise S Simpson; Victor W Day; Justin T Douglas; Peter Bosch; Christina M Dersch; Richard B Rothman; Bronwyn Kivell; Thomas E Prisinzano
Journal:  Medchemcomm       Date:  2011-12       Impact factor: 3.597

6.  Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Authors:  Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2012-07-18       Impact factor: 13.382

Review 7.  Neoclerodanes as atypical opioid receptor ligands.

Authors:  Thomas E Prisinzano
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

8.  Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.

Authors:  Ryan Vandrey; Matthew W Johnson; Patrick S Johnson; Miral A Khalil
Journal:  Adolesc Psychiatry (Hilversum)       Date:  2013-04

Review 9.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

10.  LC-MS/MS quantification of salvinorin A from biological fluids.

Authors:  Michael J Caspers; Todd D Williams; Kimberly M Lovell; Anthony Lozama; Eduardo R Butelman; Mary Jeanne Kreek; Matthew Johnson; Roland Griffiths; Katherine Maclean; Thomas E Prisinzano
Journal:  Anal Methods       Date:  2013-12-21       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.